Lower CVD Risk With Stable DMARD Therapy in Seropositive Rheumatoid Arthritis

METHODOLOGY:

The risk for CVD in patients with RA is closely associated with increasing levels of systemic inflammation; however, the risk for CVD in those with RA who are on stable DMARD therapy is still unknown.
Researchers assessed the risk for CVD in patients identified from the Norwegian Cardio-Rheuma Register who had at least two seropositive RA diagnosis codes and at least one DMARD prescription.
They classified patients into two groups: The stable treatment group, comprising patients who retained their initial DMARD throughout follow-up and had no corticosteroid prescriptions beyond the initial 6 months after diagnosis (n = 657; median age, 57 years; 64.2% women), and the nonstable treatment group, comprising the remaining patients (n = 7871; median age, 59 years; 68.8% women).
All patients were matched 1:10 to control individuals from the general population for birth year and sex.
The outcome was a five-point major adverse cardiovascular event (5p-MACE), which included acute myocardial infarction, stroke, death due to CVD, and hospitalization for unstable angina or heart failure, with follow-up until the date of outcome, death, or end of the study period, whichever occurred first.

The stable treatment and control groups had comparable baseline CVD and associated risk factors (except for diabetes), unlike the nonstable treatment group that had a higher prevalence of established CVD and associated risk factors.
The risk for 5p-MACE was lower in the stable treatment group than in the nonstable treatment group (adjusted hazard ratio [HR], 0.58; P = .039).
Moreover, patients in the nonstable treatment group had a higher likelihood of experiencing 5p-MACE than control individuals (HR, 1.39; P < .001).

Non-cardiac birth defects and long-term risk of cardiovascular hospitalisation Patients with heart defects are at risk of developing cardiovascular disease. Our objective was to determine if non-cardiac birth defects are associated with the risk of cardiovascular hospitalisation.

Urate in Atherosclerotic Plaques Boosts Risk for CV Events Patients with gout and hyperuricemia harboring cardiovascular (CV) monosodium urate (MSU) deposits in atherosclerotic plaques are at an increased risk for major adverse cardiovascular events (MACE).

Don't Overlook Underlying CV Risks In RA Treatmen Patients with rheumatoid arthritis (RA) carry a high risk for cardiovascular events, but mounting clinical evidence suggests they're being undertreated to manage that risk. Rheumatologists should consider a patient with RA's cardiovascular disease (CVD) status before deciding on RA treatments, a researcher of cardiometabolic disorders advised.

Microvascular disease and arrhythmias: a renewed focus on the myocardial microvasculature? Arrhythmias, and in particular atrial fibrillation (AF), are one of the greatest healthcare challenges of our time. Hospitalisation due to this condition is exponentially growing, and now outnumbers those for both heart failure and myocardial infarction.

In Angina, Gene Therapy Coaxes Heart Vessel Growth An experimental new gene therapy has specialists questioning whether heart vessel growth to restore blood flow could actually be possible in refractory angina after bypass surgery.